Press Release

Achieves key technical and commercial milestones

Second tranche of seed investment triggered Glythera Ltd, a UK based spin out company from the University of Bath specialising in a new generation of biological therapeutics through advanced glycosylation technologies, today announced that it had met key technical and commercial milestones as part of its Investment Agreement with the University of Bath Crescent Seedcorn fund and IP Group. Glythera will receive the second tranche of its £500,000 Investment to further advance its research in protein/peptide functionalisation and glycosylation technologies.…

Read more>>

Glythera and the FDA enter into vaccine research collaboration agreement

The FDA is to assess the feasibility of Glythera technology in developing antigenic glycoproteins as synthetic conjugate vaccines. Glythera Ltd, a UK based company specialising in developing an improved generation of biological therapeutics through advanced glycosylation technologies will collaborate with the US Food and Drug Administration (FDA) to assess the feasibility of applying Glythera's PermaLink™ technology to the generation of synthetic carbohydrate-based conjugate vaccines. The collaboration will examine the potential advantages of using Glythera's technology (PermaLink) for attaching synthetically made…

Read more>>

‹ First 

Page 10 of 10